Matthew J McConnell Selected Research

mycobactins

1/2012	Lipidomic discovery of deoxysiderophores reveals a revised mycobactin biosynthesis pathway in Mycobacterium tuberculosis.
11/2009	Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew J McConnell Research Topics

Disease

3	COVID-19 01/2022 - 01/2021
3	Infections 12/2011 - 10/2008
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Fatty Liver 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Tuberculosis (Tuberculoses) 01/2012
1	Starvation 01/2012
1	Neoplasms (Cancer) 08/2009
1	Neoplasm Metastasis (Metastasis) 08/2009
1	Lung Neoplasms (Lung Cancer) 08/2009
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2009

Drug/Important Bio-Agent (IBA)

3	Alanine Transaminase (SGPT)IBA 01/2022 - 01/2021
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 09/2021
2	von Willebrand FactorIBA 09/2021 - 01/2021
2	Fibrinogen (Factor I)FDA Link 09/2021 - 01/2021
2	LipidsIBA 01/2012 - 12/2011
2	IronIBA 01/2012 - 11/2009
2	mycobactinsIBA 01/2012 - 11/2009
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	AntigensIBA 01/2021
1	Factor VIII (Coagulation Factor VIII)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	fibrin fragment D (D-dimer)IBA 01/2021
1	MetalsIBA 01/2012
1	SiderophoresIBA 01/2012
1	Proteins (Proteins, Gene)FDA Link 08/2009
1	Tyrosine (L-Tyrosine)FDA Link 08/2009
1	Oncogene Proteins (Oncogene Protein)IBA 08/2009
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2009
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 08/2009
1	Biological ProductsIBA 10/2008

Therapy/Procedure

1	Immunotherapy 10/2008